Literature DB >> 15355922

Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells.

Stefania Gessi1, Elena Cattabriga, Arianna Avitabile, Roberta Gafa', Giovanni Lanza, Luigi Cavazzini, Nicoletta Bianchi, Roberto Gambari, Carlo Feo, Alberto Liboni, Sergio Gullini, Edward Leung, Stephen Mac-Lennan, Pier Andrea Borea.   

Abstract

PURPOSE: Adenosine is a ubiquitous nucleoside that accumulates at high levels in hypoxic regions of solid tumors, and A(3) adenosine receptors have been recently demonstrated to play a pivotal role in the adenosine-mediated inhibition of tumor cell proliferation. In the present work, we addressed the question of the putative relevance of A(3) subtypes in colorectal adenocarcinomas. EXPERIMENTAL
DESIGN: Seventy-three paired samples of tumor and surrounding peritumoral normal mucosa at a distance of 2 and 10 cm from the tumor and blood samples obtained from a cohort of 30 patients with colorectal cancer were investigated to determine the presence of A(3) receptors by means of binding, immunocytochemistry, and real-time reverse transcription-polymerase chain reaction studies.
RESULTS: As measured by receptor binding assays, the density of A(3) receptor was higher in colon carcinomas as compared with normal mucosa originating from the same individuals (P < 0.05). Overexpression of A(3) receptors at the protein level was confirmed by immunohistochemical studies, whereas no changes in A(3) mRNA accumulation in tumors as compared with the corresponding normal tissue were revealed. The overexpression of A(3) receptors in tumors was reflected in peripheral blood cells, where the density was approximately 3-fold higher compared with healthy subjects (P < 0.01). In a cohort of 10 patients studied longitudinally, expression of A(3) receptors in circulating blood cells returned to normal after surgical resection for colorectal cancer.
CONCLUSIONS: This study provides the first evidence that A(3) receptor plays a role in colon tumorigenesis and, more importantly, can potentially be used as a diagnostic marker or a therapeutic target for colon cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15355922     DOI: 10.1158/1078-0432.CCR-1134-03

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  45 in total

1.  Novel fluorescent antagonist as a molecular probe in A(3) adenosine receptor binding assays using flow cytometry.

Authors:  Eszter Kozma; T Santhosh Kumar; Stephanie Federico; Khai Phan; Ramachandran Balasubramanian; Zhan-Guo Gao; Silvia Paoletta; Stefano Moro; Giampiero Spalluto; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2012-03-01       Impact factor: 5.858

2.  Internalization and desensitization of adenosine receptors.

Authors:  Elisabeth C Klaasse; Adriaan P Ijzerman; Willem J de Grip; Margot W Beukers
Journal:  Purinergic Signal       Date:  2007-11-13       Impact factor: 3.765

3.  Gene expression profile of peripheral blood in colorectal cancer.

Authors:  Yu-Tien Chang; Chi-Shuan Huang; Chung-Tay Yao; Sui-Lung Su; Harn-Jing Terng; Hsiu-Ling Chou; Yu-Ching Chou; Kang-Hua Chen; Yun-Wen Shih; Chian-Yu Lu; Ching-Huang Lai; Chen-En Jian; Chiao-Huang Lin; Chien-Ting Chen; Yi-Syuan Wu; Ke-Shin Lin; Thomas Wetter; Chi-Wen Chang; Chi-Ming Chu
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

4.  Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity.

Authors:  Sarvesh Jajoo; Debashree Mukherjea; Kounosuke Watabe; Vickram Ramkumar
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

Review 5.  Pharmacological and therapeutic effects of A3 adenosine receptor agonists.

Authors:  Pnina Fishman; Sara Bar-Yehuda; Bruce T Liang; Kenneth A Jacobson
Journal:  Drug Discov Today       Date:  2011-10-19       Impact factor: 7.851

6.  Impact of disrupting adenosine A₃ receptors (A₃⁻/⁻ AR) on colonic motility or progression of colitis in the mouse.

Authors:  Tianhua Ren; Iveta Grants; Mazin Alhaj; Matt McKiernan; Marlene Jacobson; Hamdy H Hassanain; Wendy Frankel; Jacqueline Wunderlich; Fievos L Christofi
Journal:  Inflamm Bowel Dis       Date:  2010-12-03       Impact factor: 5.325

7.  CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.

Authors:  Salomon M Stemmer; Ofer Benjaminov; Gal Medalia; Noab B Ciuraru; Michael H Silverman; Sara Bar-Yehuda; Sari Fishman; Zivit Harpaz; Motti Farbstein; Shira Cohen; Renana Patoka; Barak Singer; William D Kerns; Pnina Fishman
Journal:  Oncologist       Date:  2013-01-08

Review 8.  Adenosine receptors as drug targets--what are the challenges?

Authors:  Jiang-Fan Chen; Holger K Eltzschig; Bertil B Fredholm
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 84.694

9.  Synthesis and characterization of [76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography.

Authors:  Dale O Kiesewetter; Lixin Lang; Ying Ma; Abesh Kumar Bhattacharjee; Zhan-Guo Gao; Bhalchandra V Joshi; Artem Melman; Sonia de Castro; Kenneth A Jacobson
Journal:  Nucl Med Biol       Date:  2009-01       Impact factor: 2.408

Review 10.  Mechanisms of induction of adenosine receptor genes and its functional significance.

Authors:  Cynthia St Hilaire; Shannon H Carroll; Hongjie Chen; Katya Ravid
Journal:  J Cell Physiol       Date:  2009-01       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.